Joanna E Zawacka-Pankau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944081/publications.pdf

Version: 2024-02-01

30 papers

1,239 citations

471509 17 h-index 30 g-index

40 all docs

40 docs citations

40 times ranked

2248 citing authors

#	Article	IF	Citations
1	ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death and Differentiation, 2014, 21, 612-623.	11.2	193
2	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease, 2018, 9, 439.	6.3	182
3	Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53. Journal of Biological Chemistry, 2011, 286, 41600-41615.	3.4	101
4	p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle, 2009, 8, 3584-3591.	2.6	81
5	Pharmacological reactivation of p53 as a strategy to treat cancer. Journal of Internal Medicine, 2015, 277, 248-259.	6.0	71
6	p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach?. Cell Cycle, 2010, 9, 720-728.	2.6	60
7	The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances. Toxicology and Applied Pharmacology, 2008, 232, 487-497.	2.8	57
8	Induction of Apoptosis in HL-60 Cells through the ROS-Mediated Mitochondrial Pathway by Ramentaceone from <i>Drosera aliciae</i> . Journal of Natural Products, 2012, 75, 9-14.	3.0	56
9	Protoporphyrin IX Interacts with Wild-type p53 Protein in Vitro and Induces Cell Death of Human Colon Cancer Cells in a p53-dependent and -independent Manner. Journal of Biological Chemistry, 2007, 282, 2466-2472.	3.4	51
10	Plumbagin Induces Apoptosis in Her2-Overexpressing Breast Cancer Cells through the Mitochondrial-Mediated Pathway. Journal of Natural Products, 2012, 75, 747-751.	3.0	51
11	The p53/MDM2/MDMX-targeted therapiesâ€"a clinical synopsis. Cell Death and Disease, 2020, 11, 237.	6.3	45
12	JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death and Disease, 2014, 5, e1484-e1484.	6.3	33
13	The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors. Frontiers in Molecular Biosciences, 2015, 2, 39.	3.5	30
14	Protoporphyrin IX induces apoptosis in HeLa cells prior to photodynamic treatment. Pharmacological Reports, 2007, 59, 474-9.	3.3	27
15	Evaluation of the Role of the Pharmacological Inhibition of <i>Staphylococcus aureus</i> Multidrug Resistance Pumps and the Variable Levels of the Uptake of the Sensitizer in the Strainâ€Dependent Response of <i>Staphylococcus aureus</i> to PPArg ₂ â€Based Photodynamic Inactivation. Photochemistry and Photobiology, 2010, 86, 1118-1126.	2.5	26
16	p53 family members – important messengers in cell death signaling in photodynamic therapy of cancer?. Photochemical and Photobiological Sciences, 2015, 14, 1390-1396.	2.9	26
17	Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Cell Death Discovery, 2019, 5, 77.	4.7	24
18	Targeting of p53 and its homolog p73 by protoporphyrin IX. FEBS Letters, 2011, 585, 255-260.	2.8	19

#	Article	IF	Citations
19	The Role of p53 Family in Cancers, 2022, 14, 823.	3.7	17
20	Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in <i>TP53</i> mutant pancreatic tumors. Future Science OA, 2019, 5, FSO366.	1.9	16
21	Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells. Cell Division, 2018, 13, 10.	2.4	15
22	Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2007, 86, 35-42.	3.8	14
23	The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity. International Journal of Molecular Sciences, 2021, 22, 8512.	4.1	9
24	The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing. Cancers, 2020, 12, 2717.	3.7	8
25	Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX. Biotechnology Letters, 2007, 29, 877-883.	2.2	4
26	Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit. Cancer Letters, 2009, 280, 101-109.	7.2	4
27	The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 7213.	4.1	4
28	Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction. Toxicology and Applied Pharmacology, 2009, 241, 246-252.	2.8	3
29	Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	3
30	Mutant p53 talks to proteasomes—is there a feedback loop between Nrf2 and mutant p53?. Translational Cancer Research, 2016, 5, 733-737.	1.0	0